Summary by Moomoo AI
Kunshengtai Pharmaceutical-B (2511) announced the unaudited interim performance for the six months ended June 30, 2024. The company focuses on the research and development of biopharmaceuticals for the treatment of metabolic and digestive system diseases and has developed five candidate products, two of which are in the clinical stage. The core product HTD1801 is in a critical stage and is undergoing Phase IIb research in the United States, Hong Kong, and mainland China. The company completed patient enrollment in Phase IIb in March 2024 and plans to complete clinical trials and data reading in the first half of 2025. The loss for the period was RMB 210.9 million, compared to RMB 549.7 million for the same period last year. The company has not declared an interim dividend and continues to promote the clinical development of the candidate drug pipeline.
